Pharmaceuticals and Medical Devices Agency Deliberative Council, Medical Devices and In Vitro Diagnostics Subcommittee Meeting Held

News Highlights

On April 30, 2026, the Ministry of Health, Labour and Welfare held a meeting of the Pharmaceuticals and Medical Devices Agency Deliberative Council, Medical Devices and In Vitro Diagnostics Subcommittee. It is presumed that key matters concerning the review and approval of new medical devices and in vitro diagnostic reagents were discussed at the subcommittee meeting. It is necessary to pay attention to information that will be released separately regarding specific agenda items and approved products.

M&A Medical Editorial Department’s Perspective

The Pharmaceuticals and Medical Devices Agency Deliberative Council is the most crucial body for the approval process of medical devices and in vitro diagnostics. Its convening signifies that important decisions are made at the stage prior to the market introduction of new technologies and products. In particular, if standards and review processes for innovative technologies such as AI-equipped diagnostic support devices and advanced regenerative medicine-related products are discussed, these will directly impact the capital investment strategies of medical institutions in the future and the development of new medical services utilizing them. For example, if devices emerge that improve diagnostic accuracy for specific diseases or enable personalized treatment effects, a competitive gap may arise between medical institutions that can introduce them early and those that cannot. Furthermore, the introduction of these new technologies and products naturally requires significant investment, which can be a factor in increasing the number of medical institutions considering business expansion through M&A or acquiring technology through collaboration with other companies.

Points Raised by This News

• Impact on review and approval standards and processes for new medical devices and in vitro diagnostic reagents
• Indication of market introduction timing for innovative technologies such as AI diagnostic support and regenerative medicine fields
• Degree of impact on capital investment and medical service strategies of medical institutions
• An indispensable source of information for predicting future trends in the medical device and in vitro diagnostic reagent markets

Practical Questions Arising from This News

• Were there any medical devices or in vitro diagnostic reagents that particularly warrant attention at this subcommittee meeting?
• For what types of medical institutions and how are the newly approved medical devices expected to be utilized?
• When are these new medical devices and in vitro diagnostic reagents expected to be covered by insurance?

If You Feel “Should I Consult Too?”

Would you like to share information with experts regarding how trends at the Pharmaceuticals and Medical Devices Agency Deliberative Council will affect the approval timing, pricing, and future market competitiveness of medical devices and in vitro diagnostic reagents that your institution is considering introducing or is expected to introduce in the future, including perspectives on M&A? In particular, it is important to start considering strategies for when competing medical institutions introduce new technologies ahead of you, and options for business succession and M&A that leverage your institution’s strengths, at an early stage.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics on a complete success fee basis as an M&A support institution certified by the Small and Medium Enterprise Agency. We handle consultations with strict confidentiality. Free consultation here